〔Abstract〕 Objective To study the effect of montelukast combined with budesonide on pulmonary function and recurrence rate after treatment in children with cough variant asthma (CVA). Methods A total of 86 children with CVA in the First People's Hospital of Xinxiang City from January 2018 to January 2019 were selected, they were divided into an observation group and a control group according to different treatment methods, with 43 cases in each group. The control group was treated with inhalation budesonide suspension, and the observation group was treated with montelukast sodium combined with inhalation budesonide suspension. The curative effect, recurrence rate of 3 months follow-up, pulmonary function [forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), FEV1/FVC)] and immune function [serum immunoglobulin (Ig) M, IgG, IgA] levels before and after treatment in the two groups were analyzed. Results The total effective rate of the observation group was 95.35%, higher than 81.40% of the control group. After treatment, FEV1, FVC, FEV1/FVC, IgM, IgG and IgA in the observation group were higher than those in the control group, the recurrence rate of the observation group was 4.88%, lower than 25.71% of the control group, the differences were statistically significant (P < 0.05). Conclusion Montelukast sodium combined with inhaled budesonide suspension has a good effect on the treatment of children with CVA, which can improve their lung function and immune function, and has a low recurrence rate